These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18004083

  • 1. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
    Passardi A, Maltoni R, Milandri C, Cecconetto L, Massa I, Zoli W, Tesei A, Fabbri F, Nanni O, Amadori D.
    Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
    [Abstract] [Full Text] [Related]

  • 2. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R, Pienkowski T, Tubiana N, Vanhoefer U, Longerey B, Douville I.
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R, Lassere Y, Diaz-Canton E, Ho DH.
    Cancer Invest; 1998 Feb; 16(3):145-51. PubMed ID: 9541627
    [Abstract] [Full Text] [Related]

  • 5. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [Abstract] [Full Text] [Related]

  • 6. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B, Booser DJ, Kirshner J.
    Cancer; 2010 Mar 15; 116(6):1440-5. PubMed ID: 20091835
    [Abstract] [Full Text] [Related]

  • 7. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I.
    Cancer; 2010 May 15; 116(10):2301-6. PubMed ID: 20225231
    [Abstract] [Full Text] [Related]

  • 8. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
    Czito BG, Cohen DP, Kelsey CR, Lockhart AC, Bendell JC, Willett CG, Petros WP, D'Amico TA, Truax R, Hurwitz HI.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):1066-72. PubMed ID: 17881149
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
    Ferrero JM, Largillier R, Michel C, Amiot V, Milano G, Hébert C, Mari V, Courdi A, Figl A, Follana P, Barrière J, Chamorey E.
    Oncology; 2011 Mar 15; 81(2):73-8. PubMed ID: 21968516
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: a phase I study.
    Cortesi E, Grifalchi F, Ramponi S, Padovani A, Mancuso A, Paoluzzi L, Ferrau F, Oliva A.
    Anticancer Res; 2003 Mar 15; 23(2C):1961-6. PubMed ID: 12820487
    [Abstract] [Full Text] [Related]

  • 13. [Phase I study of orally administered UFT plus l-leucovorin].
    Horikoshi N, Aiba K, Kanamaru R, Hasegawa K, Takeda S, Taguchi T, Niitani H, Furue H, Kurihara M, Ogawa M, Abe T.
    Gan To Kagaku Ryoho; 1998 Mar 15; 25(4):531-9. PubMed ID: 9530359
    [Abstract] [Full Text] [Related]

  • 14. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.
    Am J Clin Oncol; 2006 Jun 15; 29(3):267-75. PubMed ID: 16755180
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.
    Byström P, Frödin JE, Berglund A, Wilking N, Glimelius B.
    Radiother Oncol; 2004 Feb 15; 70(2):171-5. PubMed ID: 15028404
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
    Villanueva C, Chaigneau L, Dufresne A, Thierry Vuillemin A, Stein U, Demarchi M, Bazan F, N'guyen T, Pivot X.
    Breast; 2011 Aug 15; 20(4):329-33. PubMed ID: 21439823
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):267-73. PubMed ID: 18379784
    [Abstract] [Full Text] [Related]

  • 18. UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
    Sastre J, Aranda E, Abad A, Gallego J, Manzano JL, Gómez A, Carrato A, López E, Díaz-Rubio E, TTD Group.
    Anticancer Drugs; 2006 Apr 15; 17(4):417-21. PubMed ID: 16549999
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL.
    J Clin Oncol; 2004 Sep 01; 22(17):3466-74. PubMed ID: 15277535
    [Abstract] [Full Text] [Related]

  • 20. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T, Rustum Y, Levine E, Creaven P.
    Cancer Chemother Pharmacol; 2008 Jan 01; 61(1):125-31. PubMed ID: 17426973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.